Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
MannKind Corporation - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
MNKD
Nasdaq
2836
www.mannkindcorp.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for MannKind Corporation
MannKind to Present at Upcoming Investor Conferences
- Feb 6th, 2025 9:05 pm
MannKind Corporation's (NASDAQ:MNKD) institutional investors lost 4.0% over the past week but have profited from longer-term gains
- Feb 2nd, 2025 12:16 pm
MannKind Expands Executive Leadership Team
- Jan 6th, 2025 9:30 pm
Here’s Why MannKind Corporation (NASDAQ:MNKD) Is Among the Best Diabetes Stocks to Buy Under $10
- Jan 6th, 2025 1:47 pm
Exploring 3 High Growth Tech Stocks In The United States
- Dec 23rd, 2024 2:06 pm
MannKind (NASDAQ:MNKD) pulls back 3.8% this week, but still delivers shareholders fantastic 36% CAGR over 5 years
- Dec 20th, 2024 12:41 pm
MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash
- Dec 18th, 2024 12:00 pm
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
- Dec 16th, 2024 11:05 am
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
- Dec 11th, 2024 11:00 am
MannKind Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
- Nov 9th, 2024 1:13 pm
Q3 2024 MannKind Corp Earnings Call
- Nov 8th, 2024 6:26 pm
MannKind Corp (MNKD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
- Nov 8th, 2024 7:28 am
MannKind (MNKD) Q3 2024 Earnings Call Transcript
- Nov 8th, 2024 4:15 am
MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say
- Nov 8th, 2024 12:00 am
MannKind (MNKD) Matches Q3 Earnings Estimates
- Nov 7th, 2024 10:40 pm
MannKind: Q3 Earnings Snapshot
- Nov 7th, 2024 9:34 pm
MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
- Nov 7th, 2024 9:02 pm
MannKind to Present at 2024 UBS Healthcare Conference
- Nov 5th, 2024 9:15 pm
High Growth Tech Stocks To Watch In November 2024
- Nov 4th, 2024 6:03 pm
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
- Nov 4th, 2024 11:05 am
Scroll